Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-10084-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Huixiao Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Histone Deacetylase Inhibitors, Radiation-Sensitizing Agents, Cell Movement. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: The General Scientific Research Project of Zhejiang Province, The National Natural Science Foundation of China, The Scientific Research Project of Wenzhou Medical University for Talent.
Abstract (Originalsprache)
BACKGROUND: The radiation sensitivity of tumor cells is a critical determinant of their therapeutic response to radiotherapy. Histone deacetylase 6 (HDAC6), beyond its known role in modulating tubulin acetylation and influencing cell motility, is also involved in the DNA damage response, potentially enhancing tumor cell radiosensitivity. Targeted HDAC6 inhibitors have shown substantial promise in preclinical studies aimed at increasing radiosensitivity and inhibiting cellular migration. METHODS: A new HDAC inhibitor, named OXHA, was designed by substituting the phenyl cap of SAHA with an N,5-diphenyloxazole-2-carboxamide group. The inhibitory activity of OXHA was evaluated via in vitro enzymatic assays. Its effects on tumor cell migration and radiosensitization potential were assessed using scratch wound healing assays, micronucleus formation, and clonogenic survival assays. RESULT: Enzymatic assays confirmed OXHA's selective inhibition of HDAC6. Compared to SAHA, OXHA significantly increased α-tubulin acetylation while minimally impacting histone H3 acetylation, indicating a high selectivity for HDAC6. In combination with X-ray irradiation, OXHA markedly impaired wound healing in A549 and HepG2 cells, enhanced micronucleus formation, and reduced clonogenic survival across multiple tumor lines. CONCLUSION: OXHA exhibits potent and selective HDAC6 inhibition, effectively impeding tumor cell migration and enhancing radiosensitivity across multiple cell lines. These findings suggest that OXHA has strong potential as a therapeutic strategy to improve radiotherapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Zhejiang Engineering Research Center for Innovation and Application of Intelligent Radiotherapy Technology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
- Zhejiang Provincial Key Laboratory of Watershed Sciences and Health, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
- Wenzhou Key Laboratory of Basic Science and Translational Research of Radiation Oncology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
- School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. zhaodenggao@wyu.edu.cn.
- School of Public Health, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. brhu@wmu.edu.cn.
Förderung
- The General Scientific Research Project of Zhejiang Province
- The National Natural Science Foundation of China
- The Scientific Research Project of Wenzhou Medical University for Talent
Zitieren
APA
Hu, H., Wang, Q., Zhang, Y., Yang, S., Shen, A., Yan, J., Zhao, D., & Hu, B. (2024). Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-10084-9
Vancouver
Hu H, Wang Q, Zhang Y, Yang S, Shen A, Yan J, et al. Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-10084-9
BibTeX
@article{Hu2024,
author = {Hu, Huixiao and Wang, Qi and Zhang, Yuni and Yang, Shuhua and Shen, Aihua and Yan, Junfang and Zhao, Denggao and Hu, Burong},
title = {Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-10084-9}
}
EUVIMED